Inder S. Anand

7 ta ish

University of Minnesota

1. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

   John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi +35

   Maqola20196 iqtibos

   ABIABI:AkademIndex/2026.other.282514

2. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

   Aldo P. Maggioni, Inder S. Anand, Sidney O. Gottlieb +3

   Maqola20022 iqtibos

   ABIABI:AkademIndex/2026.other.295752

3. Spironolactone for Heart Failure with Preserved Ejection Fraction

   Bertram Pitt, Marc A. Pfeffer, Susan F. Assmann +20

   Maqola20142 iqtibos

   ABIABI:AkademIndex/2026.other.295781

4. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

   Scott D. Solomon, John J.V. McMurray, Inder S. Anand +31

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.295865

5. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

   Scott D. Solomon, Muthiah Vaduganathan, Brian Claggett +22

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.295867

6. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association

   Sheryl L. Chow, Alan S. Maisel, Inder S. Anand +11

   Sharh maqola20172 iqtibos

   ABIABI:AkademIndex/2026.other.474563

7. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone

   Amil M. Shah, Brian Claggett, Nancy K. Sweitzer +6

   Maqola20152 iqtibos

   ABIABI:AkademIndex/2026.other.613467